GB9616724D0 - Yeast strains and modified albumins - Google Patents

Yeast strains and modified albumins

Info

Publication number
GB9616724D0
GB9616724D0 GBGB9616724.2A GB9616724A GB9616724D0 GB 9616724 D0 GB9616724 D0 GB 9616724D0 GB 9616724 A GB9616724 A GB 9616724A GB 9616724 D0 GB9616724 D0 GB 9616724D0
Authority
GB
United Kingdom
Prior art keywords
pct
albumin
yeast strains
yeast
yap3p
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
GBGB9616724.2A
Other versions
GB2301365B (en
GB2301365A (en
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Albumedix Ltd
Original Assignee
Delta Biotechnology Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Delta Biotechnology Ltd filed Critical Delta Biotechnology Ltd
Publication of GB9616724D0 publication Critical patent/GB9616724D0/en
Publication of GB2301365A publication Critical patent/GB2301365A/en
Application granted granted Critical
Publication of GB2301365B publication Critical patent/GB2301365B/en
Anticipated expiration legal-status Critical
Revoked legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/58—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from fungi
    • C12N9/60—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from fungi from yeast

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Mycology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

PCT No. PCT/GB95/00434 Sec. 371 Date Nov. 11, 1996 Sec. 102(e) Date Nov. 11, 1996 PCT Filed Mar. 1, 1995 PCT Pub. No. WO95/23857 PCT Pub. Date Sep. 8, 1995Albumin, for example human albumin, is expressed and secreted in yeast which has been mutated to lack the yeast aspartyl protease 3 (Yap3p) or its equivalent, thereby reducing the production of a 45 kD albumin fragment. A further reduction is achieved by additionally deleting the Kex2p function. Alternatively, a modified albumin is prepared which is not susceptible to Yap3p cleavage, for example human albumin which is R410A, K413Q and K414Q.
GB9616724A 1994-03-05 1995-03-01 Albumin secreted from yeast having reduced levels of aspartyl protease 3 proteolytic activity, and Yap3p-resistant albumin Revoked GB2301365B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9404270A GB9404270D0 (en) 1994-03-05 1994-03-05 Yeast strains and modified albumins
PCT/GB1995/000434 WO1995023857A1 (en) 1994-03-05 1995-03-01 Yeast strains and modified albumins

Publications (3)

Publication Number Publication Date
GB9616724D0 true GB9616724D0 (en) 1996-09-25
GB2301365A GB2301365A (en) 1996-12-04
GB2301365B GB2301365B (en) 1997-07-30

Family

ID=10751353

Family Applications (2)

Application Number Title Priority Date Filing Date
GB9404270A Pending GB9404270D0 (en) 1994-03-05 1994-03-05 Yeast strains and modified albumins
GB9616724A Revoked GB2301365B (en) 1994-03-05 1995-03-01 Albumin secreted from yeast having reduced levels of aspartyl protease 3 proteolytic activity, and Yap3p-resistant albumin

Family Applications Before (1)

Application Number Title Priority Date Filing Date
GB9404270A Pending GB9404270D0 (en) 1994-03-05 1994-03-05 Yeast strains and modified albumins

Country Status (13)

Country Link
US (1) US5965386A (en)
EP (1) EP0749478B1 (en)
JP (1) JP3795073B2 (en)
KR (1) KR100372514B1 (en)
AT (1) ATE260338T1 (en)
AU (1) AU683728B2 (en)
CA (1) CA2183241C (en)
DE (1) DE69532603T2 (en)
DK (1) DK0749478T3 (en)
ES (1) ES2216007T3 (en)
GB (2) GB9404270D0 (en)
PT (1) PT749478E (en)
WO (1) WO1995023857A1 (en)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2686899B1 (en) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa NOVEL BIOLOGICALLY ACTIVE POLYPEPTIDES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
US6110703A (en) * 1996-07-05 2000-08-29 Novo Nordisk A/S Method for the production of polypeptides
DK0909312T3 (en) * 1996-07-05 2003-03-17 Novo Nordisk As Process for producing polypeptides
AU3255397A (en) * 1996-07-05 1998-02-02 Novo Nordisk A/S Method for the production of precursors of insulin, precursors of insulin analogues, and insulin like peptides
US6274305B1 (en) 1996-12-19 2001-08-14 Tufts University Inhibiting proliferation of cancer cells
US6265186B1 (en) 1997-04-11 2001-07-24 Dsm N.V. Yeast cells comprising at least two copies of a desired gene integrated into the chromosomal genome at more than one non-ribosomal RNA encoding domain, particularly with Kluyveromyces
WO1999037758A2 (en) * 1998-01-27 1999-07-29 The Board Of Regents Of The University And Community College System Of Nevada On Behalf Of The University Of Nevada-Reno Expression of proteolytically-sensitive peptides
GB9902000D0 (en) 1999-01-30 1999-03-17 Delta Biotechnology Ltd Process
CA2405557C (en) * 2000-04-12 2013-09-24 Human Genome Sciences, Inc. Albumin fusion proteins
CA2421751C (en) * 2000-09-11 2014-02-11 Donald W. Kufe Muc1 extracellular domain and cancer treatment compositions and methods derived therefrom
WO2002058450A2 (en) * 2000-12-22 2002-08-01 Dana-Faber Cancer Institute, Inc. Regulation of cell growth by muc1
US7507413B2 (en) * 2001-04-12 2009-03-24 Human Genome Sciences, Inc. Albumin fusion proteins
US20050054051A1 (en) * 2001-04-12 2005-03-10 Human Genome Sciences, Inc. Albumin fusion proteins
JP2003047471A (en) * 2001-08-01 2003-02-18 Kirin Brewery Co Ltd Modified yeast having excellent secretory production of foreign protein and method for producing foreign protein by using the yeast
US7176278B2 (en) 2001-08-30 2007-02-13 Biorexis Technology, Inc. Modified transferrin fusion proteins
WO2003059934A2 (en) 2001-12-21 2003-07-24 Human Genome Sciences, Inc. Albumin fusion proteins
US20080194481A1 (en) 2001-12-21 2008-08-14 Human Genome Sciences, Inc. Albumin Fusion Proteins
ES2545090T3 (en) 2001-12-21 2015-09-08 Human Genome Sciences, Inc. Albumin and GCSF fusion proteins
NZ534310A (en) 2002-02-07 2008-03-28 Novozymes Delta Ltd Albumin-fused anti-angiogenesis peptides
US7879365B2 (en) * 2002-02-07 2011-02-01 The Trustees Of Columbia University In The City Of New York Zinc salt compositions for the prevention of dermal and mucosal irritation
US7972809B2 (en) 2002-04-26 2011-07-05 National Institute Of Advanced Industrial Science & Technology Methylotrophic yeast producing mammalian type sugar chain
WO2004003204A1 (en) * 2002-06-29 2004-01-08 Korea Reaserch Institute Of Bioscience And Biotechnology Hansenula polymorpha yapsin deficient mutant strain and process for the preparation of recombinant proteins using the same
WO2004092339A2 (en) * 2003-04-11 2004-10-28 Ilex Products, Inc. Modulation of muc1 mediated signal transduction
US8129506B2 (en) * 2003-10-24 2012-03-06 Genzyme Corporation Modulation of the interaction of MUC1 with MUC1 ligands
GB0329681D0 (en) 2003-12-23 2004-01-28 Delta Biotechnology Ltd Gene expression technique
GB0329722D0 (en) 2003-12-23 2004-01-28 Delta Biotechnology Ltd Modified plasmid and use thereof
RU2006128593A (en) * 2004-01-07 2008-02-20 Тримерис, Инк. (Us) SYNTHETIC PEPTIDES, Derivatives of the HR2 PROTEIN GP41 HIV, AND THEIR APPLICATION IN THERAPY FOR INHIBITING THE PERMISSION OF HUMAN IMMUNODEFICIENCY VIRUS
JP2007523214A (en) * 2004-02-23 2007-08-16 ジェンザイム コーポレイション Method for enhancing MUC1 antagonist of death receptor ligand-induced apoptosis
ES2529451T3 (en) 2004-09-23 2015-02-20 Vasgene Therapeutics, Inc. Polypeptide compounds to inhibit angiogenesis and tumor growth
DK2330200T3 (en) 2004-12-23 2017-07-24 Albumedix As GENE EXPRESSION TECHNIQUE
CA2626082C (en) 2005-10-13 2017-04-11 Human Genome Sciences, Inc. Methods and compositions for use in treatment of patients with autoantibody positive disease
CA2651793C (en) 2006-02-02 2015-07-07 Trimeris, Inc. Hiv fusion inhibitor peptides with improved biological properties
JP5102833B2 (en) 2006-07-24 2012-12-19 バイオレクシス ファーマシューティカル コーポレーション Exendin fusion protein
EP2054437A2 (en) * 2006-08-07 2009-05-06 Teva Biopharmaceuticals USA, Inc. Albumin-insulin fusion proteins
DK2615108T3 (en) 2006-09-08 2017-01-30 Ambrx Inc Modified human plasma polypeptide or fc scaffolds and their applications
WO2008097844A2 (en) * 2007-02-02 2008-08-14 Dana -Farber Cancer Institute, Inc. Methods and compositions relating to the regulation of apoptosis by muc1 and bh3- containing proapoptotic proteins
WO2008097840A2 (en) 2007-02-02 2008-08-14 Dana-Farber Cancer Institute, Inc. Methods and compositions relating to the regulation of muc1 by hsf1 and stat3
KR20100016142A (en) * 2007-04-03 2010-02-12 트라이머리스, 인코퍼레이티드 Novel formulations for delivery of antiviral peptide therapeutics
EP2594583A1 (en) 2007-08-08 2013-05-22 Novozymes Biopharma DK A/S Transferrin variants and conugates
WO2009042194A2 (en) * 2007-09-25 2009-04-02 Trimeris, Inc. Methods of synthesis for therapeuthic anti-hiv peptides
JP2012516878A (en) 2009-02-06 2012-07-26 ノボザイムス バイオファーマ デーコー アクティーゼルスカブ Purification process
SG2014012918A (en) 2009-02-11 2014-04-28 Novozymes Biopharma Dk As Albumin variants and conjugates
CN105567699A (en) * 2009-10-30 2016-05-11 诺维信生物制药丹麦公司 Albumin variants
JP5850848B2 (en) 2009-11-25 2016-02-03 ノヴォ ノルディスク アー／エス Method for producing polypeptide
CA2789337A1 (en) 2010-02-16 2011-08-25 Medimmune, Llc Hsa-related compositions and methods of use
DK2554656T3 (en) * 2010-03-26 2018-07-23 Asahi Group Holdings Ltd Method of cultivating yeast
WO2011124718A1 (en) 2010-04-09 2011-10-13 Novozymes A/S Albumin derivatives and variants
US9045564B2 (en) 2011-02-15 2015-06-02 Medimmune, Llc HSA-related compositions and methods of use
WO2012112188A1 (en) * 2011-02-15 2012-08-23 Medimmune, Llc Hsa-related compositions and methods of use
CA2828811C (en) 2011-03-03 2021-09-21 Zymeworks Inc. Multivalent heteromultimer scaffold design and constructs
CN104011072B (en) 2011-05-05 2018-10-12 阿尔布梅迪克斯医疗有限公司 albumin variants
US20140315817A1 (en) 2011-11-18 2014-10-23 Eleven Biotherapeutics, Inc. Variant serum albumin with improved half-life and other properties
EP3330283A3 (en) 2012-03-16 2018-07-11 Albumedix A/S Albumin variants
CA2878640C (en) 2012-07-13 2023-10-24 Zymeworks Inc. Multivalent heteromultimer scaffold design and constructs
US20140128326A1 (en) 2012-11-08 2014-05-08 Novozymes Biopharma Dk A/S Albumin variants
CA2903739A1 (en) 2013-03-06 2014-09-12 Glaxosmithkline Llc Host cells and methods of use
EP2968587A2 (en) 2013-03-13 2016-01-20 Bristol-Myers Squibb Company Fibronectin based scaffold domains linked to serum albumin or a moiety binding thereto
WO2015001460A2 (en) * 2013-07-01 2015-01-08 Biocon Limited Signal sequence for protein expression in pichia pastoris
CA2989966C (en) 2015-08-20 2024-04-30 Albumedix A/S Albumin variants and conjugates
CA3117961A1 (en) 2018-10-29 2020-05-07 Spin Therapeutics, Llc Compositions and methods for alpha-1-antitrypsin disorders
US11739166B2 (en) 2020-07-02 2023-08-29 Davol Inc. Reactive polysaccharide-based hemostatic agent
CN114957448B (en) * 2022-06-08 2023-08-25 中国农业科学院生物技术研究所 Yeast strain for efficiently expressing alpha-lactalbumin, alpha-lactalbumin and application thereof
CN118580980B (en) * 2024-08-07 2024-10-15 通化安睿特生物制药股份有限公司 Recombinant engineering bacterium for preparing recombinant human albumin and application thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01240191A (en) * 1988-02-16 1989-09-25 Green Cross Corp:The Novel signal peptide functioning by yeast and secretory manifestation of foreign protein using same
ATE157703T1 (en) * 1991-12-16 1997-09-15 Ciba Geigy Ag ENDOPLASMATIC RETICULUM PERMANENT RECOMBINANT DIBASIC ENDOPROTEASE AND USES THEREOF
US5440018A (en) * 1992-05-20 1995-08-08 The Green Cross Corporation Recombinant human serum albumin, process for producing the same and pharmaceutical preparation containing the same

Also Published As

Publication number Publication date
DE69532603D1 (en) 2004-04-01
KR100372514B1 (en) 2004-04-30
WO1995023857A1 (en) 1995-09-08
AU1818395A (en) 1995-09-18
JPH09509581A (en) 1997-09-30
US5965386A (en) 1999-10-12
GB9404270D0 (en) 1994-04-20
ATE260338T1 (en) 2004-03-15
EP0749478A1 (en) 1996-12-27
GB2301365B (en) 1997-07-30
CA2183241A1 (en) 1995-09-08
DE69532603T2 (en) 2005-01-05
GB2301365A (en) 1996-12-04
CA2183241C (en) 2002-05-21
JP3795073B2 (en) 2006-07-12
ES2216007T3 (en) 2004-10-16
EP0749478B1 (en) 2004-02-25
AU683728B2 (en) 1997-11-20
DK0749478T3 (en) 2004-06-28
PT749478E (en) 2004-07-30

Similar Documents

Publication Publication Date Title
GB9404270D0 (en) Yeast strains and modified albumins
WO1996017924A3 (en) Novel hedgehog-derived polypeptides
GR3035568T3 (en) Yeast strains
GB2197324B (en) Process for the production of a polypeptide
CA2189657A1 (en) Lag-3 protein soluble polypeptide fractions, method of production, therapeutic composition and anti-idiotype antibody
DK0423302T3 (en) Use of novel DNA fragments as coding sequence for a signal peptide for secretion of mature proteins in recombinant yeast, expression cassettes, transformed yeast and similar method for producing proteins
ATE275343T1 (en) PROCESSING OF PLANT MATERIAL WITH XYLANASE
IL110829A0 (en) Hybrid toxin fragments and toxins comprising them
NZ510385A (en) E. coli enterotoxin II signal peptide and a microorganism expressing a fusion protein of the MST peptide and a heterologous protein, such as human growth hormone
DE59101889D1 (en) VARIANT CD44 SURFACE PROTEINS, THESE ENCODING DNA SEQUENCES, ANTIBODIES AGAINST THESE PROTEINS, AND THEIR USE IN DIAGNOSTICS AND THERAPY.
DE69431601D1 (en) NEW USE OF DEXMEDETOMIDIN
BG103016A (en) Polypeptides capable of forming antigen-binding structures of specificity to rhesus d antigens, their encoding dna and method for their prparation and application
EP0728191A4 (en) A secretion sequence for the production of a heterologous protein in yeast
CA2076678A1 (en) Improved chimeric toxins
EP0446315A4 (en) Recombinant product
ATE371027T1 (en) HUMAN INTERFERON ALPHA EXPRESSION AND SECRETION VECTOR AND METHOD FOR PRODUCING INTERFERON ALPHA BY USING THE SAME
AU4664489A (en) Ancrod proteins, their production and use
CA2089760A1 (en) Process for producing metal hydroxides with a small specific area
AU3476895A (en) Novel method for producing citric acid
DE59611353D1 (en) TRANSKETOLASE-RELATED PROTEIN
ES2155768A1 (en) Hamster protein cloned to reduce hamster allergy risk consists of a hamster product of immunoglobins uniting antigen specific IgE material
UA19652A (en) Method for prevention of broncho-pulmonary diseases in children

Legal Events

Date Code Title Description
773K Patent revoked under sect. 73(2)/1977

Free format text: PATENT REVOKED ON 20050919